© 2021 MJH Life Sciences™ and Ophthalmology Times. All rights reserved.
Latest Conference Articles
ARVO sets stage for virtual event
April 12th 2021
‘Revolutionary Eye and Vision Research’ theme of annual meeting.
Expert on IFIS offers practical pearls for success
February 22nd 2021
Cataract surgeons must consider medication history as part of preoperative evaluation.
The latest updates in cyclophotocoagulation
February 13th 2021
Shan C. Lin, MD, co-research director, Glaucoma Center of San Francisco, speaks on the highlights from his presentation on the latest in the three forms of cyclophotocoagulation commonly used by clinicians.
Intersection of glaucoma and retina at the pars plana
February 11th 2021
J. Michael Jumper, MD, a retinal specialist at West Coast Retina (San Francisco, CA), discusses the highlights of his Glaucoma 360 presentation analyzing the impact and lasting effects of intraocular injections and retinal diseases in creating glaucoma as well as the evolving collaboration between retinal and glaucoma specialists.
Managing secondary glaucoma due to intravitreal steroids
February 9th 2021
L. Jay Katz, MD, of the Wills Eye Hospital, Philadelphia, PA, discusses the highlights of his Glaucoma 360 presentation on secondary glaucoma due to intravitreal steroids, and what ophthalmologists can do to minimize the risk of severe visual impairment in patients.
Aerie COO: Expanding innovation of glaucoma therapeutics
February 6th 2021
Tom Mitro, president, COO of Aerie Pharmaceuticals, discusses the key highlights from an industry panel discussion titled "Innovate without borders," held during the Glaucoma 360 New Horizons Forum, including the company's role in expanding into the global glaucoma therapeutics market.
Tarsus execs discuss origins, treating Demodex blepharitis
February 4th 2021
Tarsus Pharmaceuticals's CEO Bobby Azamian, MD, PhD, and Chairman Michael Ackermann, PhD, speak on the development of their company and the latest updates on their lead candidate product to treat Demodex blepharitis.
Glaucoma care after COVID-19: The Pan-American view
January 31st 2021
Results of a survey among ophthalmologists indicate that patients are receiving fewer examinations — with worsening glaucoma, says S. Fabian Lerner, MD, speaking at the Glaucoma 360 New Horizons Forum.
Multi-pressure dial: A new approach to lowering IOP and treating glaucoma
January 31st 2021
A new therapy provides noninvasive nighttime IOP control by programming the desired pressure into the device, explained John Berdahl, MD, during the New Horizons Forum.
Glaukos COO shares product updates, 2021 pipeline
January 31st 2021
Glaukos Corporation's COO Chris Calcaterra gives an update on the company's latest 24-month phase 2b data for its iDose TR sustained-release travoprost implant, next steps for securing FDA approval, and his outlook for 2021.